Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ispinesib - Cytokinetics

Drug Profile

Ispinesib - Cytokinetics

Alternative Names: 715992; CK 0238273; Ispinesib mesilate; Ispinesib mesylate; SB-715992; SB-715992-S

Latest Information Update: 08 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytokinetics
  • Class Antineoplastics; Benzamides; Quinazolines; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Colorectal cancer; Haematological malignancies; Renal cancer; Solid tumours
  • Discontinued Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 26 Apr 2019 Discontinued - Phase-I/II for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Peru (IV) (NCT00607841)
  • 20 Jul 2012 The National Cancer Institute, in collaboration with GlaxoSmithKline, completes a phase II trial in Renal cancer in the US (NCT00354250)
  • 04 Nov 2010 Suspended - Phase-I for Haematological malignancies in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top